SG11201912683QA - Treatment agent for epidermolysis bullosa - Google Patents

Treatment agent for epidermolysis bullosa

Info

Publication number
SG11201912683QA
SG11201912683QA SG11201912683QA SG11201912683QA SG11201912683QA SG 11201912683Q A SG11201912683Q A SG 11201912683QA SG 11201912683Q A SG11201912683Q A SG 11201912683QA SG 11201912683Q A SG11201912683Q A SG 11201912683QA SG 11201912683Q A SG11201912683Q A SG 11201912683QA
Authority
SG
Singapore
Prior art keywords
treatment agent
epidermolysis bullosa
bullosa
epidermolysis
agent
Prior art date
Application number
SG11201912683QA
Inventor
Hiroshi Shimizu
Yasuyuki Fujita
Naoya Masutomi
Original Assignee
Univ Hokkaido Nat Univ Corp
Life Science Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Hokkaido Nat Univ Corp, Life Science Institute Inc filed Critical Univ Hokkaido Nat Univ Corp
Publication of SG11201912683QA publication Critical patent/SG11201912683QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0629—Keratinocytes; Whole skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201912683QA 2017-06-19 2018-06-19 Treatment agent for epidermolysis bullosa SG11201912683QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017119854 2017-06-19
PCT/JP2018/023352 WO2018235834A1 (en) 2017-06-19 2018-06-19 Treatment agent for epidermolysis bullosa

Publications (1)

Publication Number Publication Date
SG11201912683QA true SG11201912683QA (en) 2020-01-30

Family

ID=64737127

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912683QA SG11201912683QA (en) 2017-06-19 2018-06-19 Treatment agent for epidermolysis bullosa

Country Status (9)

Country Link
US (1) US20200206272A1 (en)
EP (1) EP3643316A4 (en)
JP (2) JPWO2018235834A1 (en)
KR (1) KR20200016298A (en)
CN (1) CN110831607A (en)
AU (1) AU2018289935A1 (en)
CA (1) CA3067963A1 (en)
SG (1) SG11201912683QA (en)
WO (1) WO2018235834A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2020149395A1 (en) * 2019-01-18 2021-11-25 国立大学法人大阪大学 Drug for treating epidermolysis bullosa
US20230203436A1 (en) 2020-04-02 2023-06-29 Tohoku University High-potential pluripotent stem cells
WO2022018884A1 (en) * 2020-07-22 2022-01-27 国立大学法人大阪大学 Therapeutic agent for dystrophic epidermolysis bullosa
WO2023164241A1 (en) * 2022-02-28 2023-08-31 Jlm Exograde, Llc Method for enriching muse cells and obtaining exosomes, microvesicles or the secretome therefrom

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5185443A (en) 1975-09-12 1976-07-27 Hitachi Ltd KENSHUTSU KAIRO
JP2014133703A (en) * 2011-03-30 2014-07-24 Clio Inc Composition for cell therapy for allotransplant including ssea-3 positive pluripotent stem cell that can be isolated from biological tissue
US9399758B2 (en) * 2009-07-15 2016-07-26 Mari Dezawa SSEA3(+) pluripotent stem cell that can be isolated from body tissue
US9550975B2 (en) * 2009-07-15 2017-01-24 Mari Dezawa SSEA-3 pluripotent stem cell isolated from body tissue
JP2014132830A (en) * 2011-03-30 2014-07-24 Clio Inc Pluripotent stem cell that can be isolated from umbilical cord or adipose tissue of living body
AU2012345630A1 (en) * 2011-11-30 2014-07-17 Astellas Institute For Regenerative Medicine Mesenchymal stromal cells and uses related thereto
WO2014163206A1 (en) * 2013-04-02 2014-10-09 Clio, Inc. Use of functional melanocytes readily differentiated from multilineage-differentiating stress-enduring (Muse) cells, distinct stem cells in human fibroblasts
JP6452107B2 (en) * 2014-09-05 2019-01-16 国立大学法人 東京大学 Pluripotent stem cells for the treatment of diabetic skin ulcers

Also Published As

Publication number Publication date
EP3643316A4 (en) 2021-01-20
EP3643316A1 (en) 2020-04-29
JP2023060125A (en) 2023-04-27
CA3067963A1 (en) 2018-12-27
CN110831607A (en) 2020-02-21
JPWO2018235834A1 (en) 2020-04-16
KR20200016298A (en) 2020-02-14
WO2018235834A1 (en) 2018-12-27
US20200206272A1 (en) 2020-07-02
AU2018289935A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
GB201700991D0 (en) Aneurysm treatment apparatus
IL269371A (en) Treatment methods
IL273407A (en) Methods and compositions for the treatment of epidermolysis bullosa
IL266530A (en) Treatment for fibrosis
GB201608885D0 (en) Treatment
SG11201912683QA (en) Treatment agent for epidermolysis bullosa
IL254173B (en) Oligonucleotides matching col7a1 exon 73 for epidermolysis bullosa therapy
EP3373951A4 (en) Methods and compositions for the treatment of epidermolysis bullosa
SG11201704499WA (en) Agent for hair deforming treatment
SG11201704497PA (en) Agent for hair deforming treatment
GB2567616B (en) Treatment method
SG11201701982QA (en) Methods of treating graft versus host disease (gvhd) or epidermolysis bullosa (eb) with exosomes
GB201502404D0 (en) Water treatment
SG11201704504PA (en) Agent for hair deforming treatment
EP3515452C0 (en) Treatment of restenosis using temsirolimus
GB2571601B (en) Treatment method
HK1255224A1 (en) Wound treatment agent
SG11201710686PA (en) Hair treatment agent
HK1245826A1 (en) Antisense oligonucleotides to treat dystrophic epidermolysis bullosa
SG11201704493UA (en) Agent for hair deforming treatment
PL3580182T3 (en) Water treatment
IL276966A (en) Epilepsy treatment agent
HK1244438A1 (en) Polymer treatment agent
GB201718985D0 (en) Treatment
GB201713650D0 (en) Treatment